Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics
- PMID: 29940717
- PMCID: PMC6018140
- DOI: 10.30773/pi.2018.01.18.1
Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics
Abstract
Objective: Second-generation antipsychotics (SGAs) increase the risk of metabolic syndrome (MetS). Despite the risk of MetS, SGAs may have to be continued with change in some patients. The aim of this study was to trace the evolution of MetS in these patients.
Methods: Patients with schizophrenia who had been maintained on a fixed SGA regimen for more than a year were followed-up without changing the regimen. Metabolic indicators were evaluated at baseline and at follow-up. Prevalence, incidence and spontaneous normalization rate of MetS were estimated. Risk factors that might have influenced the evolution were scrutinized.
Results: A total of 151 subjects were included. During the mean observation period of 389.9±162.4 days, the prevalence of MetS was increased from 35.1 to 45.0%. The incidence rate was 29.6%, while the normalization rate was 26.4%, risk factors affecting incidence were age (OR=1.09, 95% CI: 1.03-1.17), baseline continuous values of metabolic syndrome risk scores (cMetS, OR=1.77, 95% CI:1.29-2.55) and baseline body weight (OR=1.06, 95% CI: 1.01-1.13). Normalization was influenced by age (OR=0.74, 95% CI: 0.57-0.89) and baseline body weight (OR=0.85, 95% CI: 0.72-0.95).
Conclusion: The prevalence of MetS steadily increased with the continuous use of SGAs. However, individual difference was extensive and about a quarter of the patients were able to recover naturally without specific measurements.
Keywords: Incidence; Metabolic syndrome; Normalization; Schizophrenia; Second-generation antipsychotics.
Figures

Similar articles
-
Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review.Schizophr Res. 2008 Apr;101(1-3):295-303. doi: 10.1016/j.schres.2008.01.028. Epub 2008 Mar 4. Schizophr Res. 2008. PMID: 18299188 Clinical Trial.
-
Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review.Front Psychiatry. 2021 Mar 29;12:625935. doi: 10.3389/fpsyt.2021.625935. eCollection 2021. Front Psychiatry. 2021. PMID: 33868046 Free PMC article.
-
Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics.Neuropsychiatr Dis Treat. 2019 Jul 29;15:2161-2170. doi: 10.2147/NDT.S202159. eCollection 2019. Neuropsychiatr Dis Treat. 2019. PMID: 31534339 Free PMC article.
-
Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics.Bipolar Disord. 2008 Nov;10(7):788-97. doi: 10.1111/j.1399-5618.2008.00625.x. Bipolar Disord. 2008. PMID: 19032710
-
Second-generation antipsychotics and metabolic syndrome: a role for mitochondria.Front Psychiatry. 2023 Nov 24;14:1257460. doi: 10.3389/fpsyt.2023.1257460. eCollection 2023. Front Psychiatry. 2023. PMID: 38076704 Free PMC article. Review.
Cited by
-
Effects of Short-term Mobile Application Use on Weight Reduction for Patients with Type 2 Diabetes.J Obes Metab Syndr. 2021 Dec 30;30(4):345-353. doi: 10.7570/jomes21047. J Obes Metab Syndr. 2021. PMID: 34875628 Free PMC article.
-
Correlations between Body Mass Index, Plasma High-Sensitivity C-Reactive Protein and Lipids in Patients with Schizophrenia.Psychiatr Q. 2019 Mar;90(1):101-110. doi: 10.1007/s11126-018-9606-3. Psychiatr Q. 2019. PMID: 30315442
-
Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction.Int J Mol Sci. 2022 Jun 25;23(13):7092. doi: 10.3390/ijms23137092. Int J Mol Sci. 2022. PMID: 35806096 Free PMC article. Review.
-
Association Between Prolactin, Estradiol, and Testosterone Levels and the Development of Metabolic Syndrome in Female Inpatients with Schizophrenia: A Case-Control Study.Psychiatr Q. 2023 Jun;94(2):211-220. doi: 10.1007/s11126-023-10025-y. Epub 2023 May 1. Psychiatr Q. 2023. PMID: 37126196 Free PMC article.
-
Relationship Between Family Support, C-Reactive Protein and Body Mass Index Among Outpatients with Schizophrenia.Healthcare (Basel). 2025 Jul 20;13(14):1754. doi: 10.3390/healthcare13141754. Healthcare (Basel). 2025. PMID: 40724779 Free PMC article.
References
-
- Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123–1131. - PubMed
-
- Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of secondgeneration antipsychotics. Arch Gen Psychiatry. 2003;60:553–564. - PubMed
-
- Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med. 2009;39:1591–1602. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources